NRx Pharmaceuticals (Nasdaq: NRXP) said its subsidiary HOPE Therapeutics will be the first interventional psychiatry network to deploy Zeta Surgical's FDA-cleared Zeta TMS Robotic System, with clinical staff training at Zeta's Boston headquarters ahead of deployment at HOPE clinics in Florida. The system uses AI-driven software, a neurosurgical robotic arm and movement tracking to adjust the TMS coil in real time with submillimeter precision. It builds on the Zeta TMS Navigation System, which HOPE became the first commercial U.S. site to use for patient treatment in June 2026. The deployment supports SPARC-TMS, NRx's FDA-approved Phase 2/3 trial of NRX-101 combined with robotic TMS (NCT07227103). NRx was selected by the Defense Advanced Research Projects Agency as the trial's prime contractor, subject to completion of contracting, and the trial is planned across a leading U.S. academic teaching hospital, HOPE clinics and two military treatment facilities. NRx also said it is initiating a military project in partnership with Harvard McClean Hospital. The company is participating in a fireside chat at the 2026 Cantor Global Healthcare Conference on Sept. 11 at 8:35 a.m. ET, with a webcast available on its investor-relations website. TMS is used primarily for treatment-resistant depression, which affects about one-third of people with major depressive disorder.